Results 111 to 120 of about 1,886 (182)

Electro-clinical features and management of the late stage of Lafora disease. [PDF]

Front Neurol, 2022
d'Orsi G, Di Claudio MT, Palumbo O, Carella M.   +3 more
europepmc   +1 more source

A Second Gene for Lafora Disease [PDF]

Epilepsy Currents, 2004
openaire   +2 more sources

Trehalose Treatment in Zebrafish Model of Lafora Disease. [PDF]

Int J Mol Sci, 2022
Della Vecchia S, Ogi A, Licitra R, Abramo F, Nardi G, Mero S, Landi S, Battini R, Sicca F, Ratto GM, Santorelli FM, Marchese M.   +11 more
europepmc   +1 more source

Neurofilament Light Chain as a Biomarker of Disease Progression in Lafora Disease. [PDF]

Neurol Genet
Muccioli L, Ganceviciute B, Becker F, Minardi R, Tappatà M, Bachhuber F, Alkhatib M, Cirak S, Weishaupt J, Verma M, Tumani H, Wagner J, Messahel S, Nitschke F, Minassian BA, Bisulli F, Brenner D.   +16 more
europepmc   +1 more source

Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in <i>Epm2b</i>-Deficient Mice. [PDF]

Int J Mol Sci
Zafra-Puerta L, Iglesias-Cabeza N, Sanz P, García-Gimeno MA, Sánchez-Martín G, Sánchez MP, Serratosa JM.   +6 more
europepmc   +1 more source

Lafora disease: Current biology and therapeutic approaches. [PDF]

Rev Neurol (Paris), 2022
Mitra S, Gumusgoz E, Minassian BA.
europepmc   +1 more source

Clinical course and management challenges in Lafora disease: a narrative analysis in an Apulian cohort. [PDF]

Orphanet J Rare Dis
d'Orsi G, Di Claudio MT, Liantonio A, Imbrici P, Altomare CD, Palumbo O, Palumbo P, Benvenuto M, Gambacorta N, Lolli G, DEFEAT-LD study group, Carella M.   +11 more
europepmc   +1 more source

Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model. [PDF]

Mol Neurobiol, 2022
Mollá B, Heredia M, Campos Á, Sanz P.
europepmc   +1 more source

Diagnosis of Lafora Disease by Skin Biopsy [PDF]

Journal of Clinical and Diagnostic Research, 2017
Prasath Sathiah, Debasis Gochhait, Priyadarshini Dehuri, Hema Subramanian   +3 more
doaj   +1 more source

New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment. [PDF]

Neurotherapeutics
Muccioli L, Tappatà M, Farolfi A, Singh PK, Pasini E, Mazzone S, Esposito E, Motta L, D'Agati OM, Angeloni S, Caravelli A, Cancellerini C, Minardi R, Pizzi E, Carelli V, Tonon C, Fiori J, Gentry MS, Vignatelli L, Michelucci R, Bisulli F, DEFEAT-LD study group.   +21 more
europepmc   +1 more source